Scientists investigate relapse after CAR t: blood draws hold clues
NCT ID NCT05397132
First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study tracks 50 people with blood cancers who are receiving CAR T therapy. Researchers will take blood samples over time to measure immune cells and genetic changes. The goal is to find patterns that predict or explain why the cancer comes back. This is an observational study, not a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors understand why some patients relapse after CAR T therapy, leading to better treatment strategies.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly improve outcomes, and results may take years to apply.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
88 people
The number who actually took part.
- Started
-
May 2022
- Finished
-
Feb 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines. 2. Has a confirmed diagnosis of hematologic malignancy and will be undergoing CAR T therapy with commercial CAR T product. 3. Patient who has a confirmed diagnosis of hematologic malignancy and will be receiving CAR T therapy under clinical trial protocol will also be eligible if the clinical trial sponsor and the investigator approve patient participation in the study. Exclusion Criteria: * NA
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hematologic malignancy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can regional data improve bone marrow transplant results for blood cancers?
- Could a frailty score predict which older cancer patients survive intensive care?
- Why COVID-19 hits blood cancer patients harder: scientists map the immune clues
- Softer chemo before stem cell transplant aims to cure blood cancers in frail children
- Can a new drug stop the Body's attack after stem cell transplants?
- Wearable patches could spot heart danger hiding in cancer treatment